Nacubactam (RG6080, OP0595) extends Meropenem efficacy in murine septicemia model induced by OXA-, KPC- and NDM-producing Klebsiella pneumoniae clinical isolates

Increasing resistance toward β-lactam antibiotics, especially carbapenems, poses a serious therapeutic challenge in clinical setting. Among the Carbapenem-resistant Enterobactariaceae (CREs), β-lactamase producing K. pneumoniae isolates are becoming increasingly prevalent worldwide and their multidrug resistance is limiting the therapeutic options available for treating infections.

This study aimed to determine the in vivo efficacy of the combination MEM/NAC in a murine septicemia model induced by K. pneumoniae clinical isolates expressing carbapenem-hydrolysing serine active site - KPC-2, KPC-3, OXA-48 – and metallo-ß-lactamases (NDM-1).

Recently presented by our experts in collaboration with Roche Pharma at the ECCMID 2018 conference, download your copy of this educational scientific poster now and discover more.

Nacubactam (RG6080, OP0595) Extends Meropenem Efficacy in Murine Septicemia Model Induced by OXA-, KPC- and NDM-producing Klebsiella pneumoniae Clinical Isolates

Get your copy today!

Download our poster now